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IL: interleukin 
JNK: c-Jun N-terminal kinase 
MAPK: mitogen-activated protein kinases 
STAT: signal transducer and activator of transcription 
TGF-β1: transforming growth factor-β1 
TLR: toll-like receptor 


















Transforming growth factor (TGF)-β1 is a multifunctional cytokine, which can control 
certain functions of various kinds of cells. However, it is unclear whether TGF-β1 affects 
T-cell migration in periodontal lesions. The aim of this study was to examine the effects of 
TGF-β1 on the production of C-C chemokine ligand (CCL)11, which is a T-helper 2-type 
chemokine, in human periodontal ligament cells (HPDLC). Interleukin (IL)-4 induced 
CCL11 production, but TGF-β1 did not, in HPDLC. However, TGF-β1 enhanced CCL11 
production in IL-4-stimulated HPDLC. Western blot analysis showed that the signal 
transducer and activator of transcription 6 (STAT6) pathway was highly activated in HPDLC 
that had been stimulated with both IL-4 and TGF-β1. Mitogen-activated protein kinase 
activation did not differ between the HPDLC treated with a combination of IL-4 and TGF-β1 
and those treated with IL-4 or TGF-β1 alone. Moreover, a STAT6 inhibitor significantly 
inhibited CCL11 production in HPDLC that had been stimulated with IL-4 and TGF-β1. The 
current study clearly demonstrated that TGF-β1 enhanced IL-4-induced CCL11 production in 
HPDLC. The STAT6 pathway is important for CCL11 production in IL-4- and 





1. Introduction  
Host responses to bacteria in periodontal lesions are involved in the progression of 
periodontal disease [Cekiti et al., 2014]. In particular, T cells are associated with the 
pathogenesis of chronic periodontal disease. Garlet reported that cytokines from T-helper 
(Th)1 cells and Th17 cells increased receptor activator of nuclear factor kappa-β ligand 
(RANKL) levels and induced bone resorption in periodontal lesions. He also suggested that 
cytokines from Th2 cells might antagonize the destructive events induced by Th1 and Th17 
cells [Garlet, 2010]. On the other hand, it has been reported that Th2 cells are involved in the 
pathogenesis of periodontal disease. Myneni et al. demonstrated that Tannerella 
forsythia-induced Toll-like receptor (TLR)2 activation resulted in alveolar bone destruction in 
a mouse model. Furthermore, Th2 cell proliferation downstream of TLR2 activation was 
found to be associated with alveolar bone destruction caused by Tannerella forsythia [Myneni 
et al., 2011]. The role of Th2 cells in periodontal lesions is still disputed. However, it is 
important to elucidate the mechanism responsible for Th2 cell migration and accumulation in 
periodontal lesions because Th2 cells are obviously involved in the pathological process 
responsible for periodontal disease. 
Th2 cells preferentially express C-C chemokine receptor type 3 (CCR3), and C-C chemokine 
ligand (CCL)11, which is a CCR3 ligand, is found in the gingival crevicular fluid of patients 
with periodontal disease [Sallusto et al., 1997; Thunell et al., 2010]. Therefore, we examined 
whether periodontal resident cells produce CCL11. As a result, we revealed that treatment 
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with interleukin (IL)-4 in combination with IL-1β or tumor necrosis factor (TNF)-α induced 
CCL11 production in human gingival fibroblasts [Hosokawa et al., 2013]. However, it is 
unclear whether other cytokines modulate CCL11 production. 
Transforming growth factor (TGF)-β1 is a multifunctional cytokine, which modulates various 
functions in many different cell types [Grotendorst et al., 1997; Lawrence et al., 1996]. For 
example, TGF-β1 inhibits the proliferation of most cells. However, TGF-β1 enhances the 
growth of some kinds of mesenchymal cells [Lawrence et al., 1996]. TGF-β1 has 
immunosuppressive effects on certain types of cells, which involve the inhibition of 
proinflammatory cytokine production [Lawrence et al., 1996]. TGF-β1 also induces the 
production of extracellular matrix molecules [Lawrence et al., 1996]. Recently, it was 
reported that compared with healthy tissue, tissue affected by periodontal disease exhibits 
elevated TGF-β1 expression [Khalaf et al., 2014]. However, there have been few reports 
about the effects of TGF-β1 on chemokine production, and it is unclear whether TGF-β1 
modulates CCL11 expression in periodontal ligament cells.  
The aim of this study was to investigate the effects of IL-4 and TGF-β1 on CCL11 production 
in human periodontal ligament cells (HPDLC), which are the major resident cells in 
periodontal tissues. Moreover, we examined the signal transduction pathways involved in 
CCL11 production, such as the mitogen-activated protein kinase (MAPK) and signal 
transducer and activator of transcription 6 (STAT6) pathways. 
2. Materials and Methods 
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2.1. Cell culturing 
HPDLC were obtained from Lonza Walkersville Inc. (Walkersville, MD, USA) and grown in 
Dulbecco’s modified Eagle’s medium (Gibco, Grand Island, NY, USA) supplemented with 
10% fetal bovine serum (Gibco) and antibiotics (penicillin G: 100 units/ml, streptomycin: 
100 µg/ml) at 37°C in humidified air with 5% CO2. The cells were used between passage 
numbers 5 and 10. 
2.2. CCL11 production in HPDLC 
HPDLC were stimulated with recombinant human TGF-β1 (0.01, 0.1, 1, or 10 ng/ml; 
PeproTech, Rocky Hill, NJ, USA) and/or recombinant human IL-4 (10 ng/ml; PeproTech) for 
24 hours. The HPDLC culture supernatants were collected, and their CCL11 concentrations 
were measured in triplicate with DuoSet enzyme-linked immunosorbent assays (ELISA) 
(R&D systems, Minneapolis, MN, USA). All assays were performed according to the 
manufacturer’s instructions, and cytokine levels were determined using the standard curves 
prepared for each assay. In selected experiments, HPDLC were cultured for 1 hour in the 
presence or absence of AS1517499, a STAT6 inhibitor (100 nM; Axon Medchem, Groningen, 
The Netherlands), prior to their incubation with TGF-β1 and IL-4. We used 3 samples in this 
experiment, and performed the ELISA in triplicate for each sample.  
2.3. Western blot analysis 
To confirm whether IL-4 with or without TGF-β1 induced the phosphorylation of signal 
transduction molecules in HPDLC, Western blot analysis was performed. HPDLC that had 
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been stimulated with IL-4 (10 ng/ml) with or without TGF-β1 (10 ng/ml) for 15, 30, or 60 
minutes were washed once with cold phosphate-buffered saline, before being incubated on 
ice for 15 minutes with cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) 
supplemented with protease inhibitor cocktail (Sigma, St. Louis, MO, USA). After the 
removal of debris via centrifugation, the protein concentrations of the lysates were quantified 
with the Bradford protein assay using IgG as a standard. A 20-µg protein sample was loaded 
onto 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel, before being 
electrotransferred to a polyvinylidene difluoride membrane. The phosphorylation of p38 
MAPK, extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK), and 
STAT6 in HPDLC were assessed using a phospho-p38 MAPK rabbit monoclonal antibody 
(Cell Signaling Technology), a phospho-ERK rabbit monoclonal antibody (Cell Signaling 
Technology), a phospho-JNK rabbit monoclonal antibody (Cell Signaling Technology), a 
phospho-STAT6 rabbit monoclonal antibody (Cell Signaling Technology), a p38 MAPK 
rabbit monoclonal antibody (Cell Signaling Technology), an ERK rabbit monoclonal 
antibody (Cell Signaling Technology), a JNK rabbit monoclonal antibody (Cell Signaling 
Technology), a STAT6 rabbit monoclonal antibody (Cell Signaling Technology), or a 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) rabbit monoclonal antibody (Cell 
Signaling Technology), according to the manufacturer’s instructions. The protein bands were 
incubated with the horseradish peroxidase-conjugated secondary antibody (Sigma) and then 
visualized using the ECL detection system (GE Healthcare, Uppsala, Sweden). We 
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performed Western blot analysis using 3 samples, and we obtained similar results for each 
sample. 
2.4. Statistical analysis 
All experiments were repeated 3 times and produced similar results in each case. The 
significance of differences between groups was assessed by one-way analysis of variance 
(ANOVA) in the experiments shown in Figure 1 and Figure 4. P-values of <0.05 were 
considered statistically significant. 
3. Results 
3.1. The effects of IL-4 and/or TGF-β1 on CCL11 production in HPDLC 
We first examined the effects of 24 hours’ stimulation with TGF-β1 on CCL11 production in 
HPDLC. TGF-β1 (10 ng/ml) alone did not induce CCL11 production. So, we investigated 
whether TGF-β1 is able to modulate CCL11 production induced by another cytokine. We 
previously reported that IL-4 induced CCL11 production in human gingival fibroblasts 
[Hosokawa et al., 2013]. So, we focused on IL-4 in this study. Treating the HPDLC with 10 
ng/ml IL-4 induced significant CCL11 production, but treating them with 1 ng/ml IL-4 only 
caused them to produce a small amount of CCL11. TGF-β1 significantly enhanced CCL11 
production in IL-4-stimulated HPDLC in a dose-dependent fashion (Fig. 1).  
3.2. The effects of IL-4 and/or TGF-β1 on MAPK phosphorylation in HPDLC 
We previously reported that MAPK are associated with CCL11 production in human gingival 
fibroblasts [Hosokawa et al., 2013]. Therefore, we examined MAPK activation in IL-4- 
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and/or TGF-β1-stimulated HPDLC. Figure 2 shows that stimulation with IL-4 or TGF-β1 
alone activated the p38 MAPK, ERK, and JNK pathways in HPDLC. The levels of 
phosphorylated p38 MAPK and phosphorylated JNK between the HPDLC stimulated with 
both IL-4 and TGF-β1 (hereafter referred to as the IL-4/TGF-β1-stimulated HPDLC) and 
those stimulated with the IL-4 or TGF-β1 alone. On the other hand, the ERK phosphorylation 
level of the IL-4/TGF-β1-stimulated HPDLC was lower than that seen in the 
TGF-β1-stimulated HPDLC, although similar levels of ERK phosphorylation were observed 
in the IL-4-stimulated HPDLC and IL-4/TGF-β1-stimulated HPDLC. Judging from the 
Western blot data, we consider that MAPK pathways are not involved in the enhancement of 
CCL11 production in IL-4/TGF-β1-stimulated HPDLC because TGF-β1 stimulation did not 
enhance the level of MAPK phosphorylation induced by IL-4.  
3.3. The effects of IL-4 and/or TGF-β1 on STAT6 activation in HPDLC 
Next, we examined whether IL-4 and/or TGF-β1 stimulation affected the activation of STAT6 
in HPDLC because it is known that IL-4 activates the STAT6 pathway in some types of cells 
[Takeda et al., 2000]. Figure 3 shows that IL-4 induced STAT6 phosphorylation in HPDLC 
after 15 minutes’ stimulation although TGF-β1 did not induce STAT6 activation. On the other 
hand, compared with that seen after stimulation with IL-4 alone treatment with a combination 
of IL-4 and TGF-β1 enhanced the level of STAT6 phosphorylation in the HPDLC at all time 
points. 
3.4. The effects of a STAT6 inhibitor on CCL11 production in HPDLC that had been 
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stimulated with IL-4 and TGF-β1 
Figure 3 clearly shows that stimulation with both IL-4 and TGF-β1 enhanced STAT6 
activation. Therefore, we hypothesized that the STAT6 pathway might control CCL11 
production in IL-4/TGF-β1-stimulated HPDLC. Figure 4 shows that AS1517499 (a STAT6 
inhibitor) significantly reduced CCL11 production in IL-4/TGF-β1-stimulated HPDLC. 
Moreover, AS1517499 inhibited CCL11 production in IL-4-stimulated HPDLC (data not 
shown). 
4. Discussion 
In this study, we revealed that TGF-β1 increased CCL11 production in IL-4-stimulated 
HPDLC. Matsukura et al. reported that TGF-β1 did not induce CCL11 production in human 
airway smooth muscle cells. However, they found that TGF-β1 enhanced CCL11 production 
in IL-4- or IL-13-treated human airway smooth muscle cells [Matsukura et al., 2010]. Wenzel 
et al. also reported that treatment with a combination of TGF-β1 and IL-13 synergistically 
increased CCL11 expression in human airway fibroblasts [Wenzel et al., 2002]. Judging from 
our data and those of previous reports, the number of Th2 cells in inflammatory lesions might 
markedly increase when both IL-4 and TGF-β1 are present because CCL11 production by 
host cells increases in such circumstances. A previous study detected elevated levels of 
TGF-β1 in periodontal lesions [Khalaf et al., 2014]. Therefore, the number of Th2 cells might 
markedly increase whenTh2 cells in periodontal lesions produce IL-4, and hence, IL-4 might 
be a key cytokine for Th2 cell accumulation.  
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We showed that treatment with a combination of IL-4 and TGF-β1 did not result in an 
increase in MAPK phosphorylation in HPDLC compared with stimulation with IL-4 alone 
(Fig. 2). In addition, MAPK inhibitors reduced CCL11 production in HPDLC stimulated with 
IL-4 alone or IL-4 and TGF-β1 (data not shown). Therefore, MAPK activation was not found 
to be associated with the enhanced CCL11 production seen in HPDLC treated with a 
combination of IL-4 and TGF-β1. El Mabrouk et al. reported that IL-4 did not affect p38 
MAPK or ERK phosphorylation in TGF-β1-treated human chondrocytes although JNK 
phosphorylation was inhibited by IL-4 treatment [El Mabrouk et al., 2008]. Xie et al. reported 
that IL-4 inhibited TGF-β1-stimulated ERK activation in human airway muscle cells [Xie et 
al., 2005]. Previous studies, including ours, have shown that the effects of IL-4 on MAPK 
activation in TGF-β1 are dependent on the type of cell or the cytokine concentration [El 
Mabrouk et al., 2008; Xie et al., 2005]. Our previous study demonstrated that CCL11 
production in human gingival fibroblasts was positively regulated by p38 MAPK, ERK, and 
JNK [Hosokawa et al., 2013]. However, the level of MAPK phosphorylation in IL-4-treated 
HPDLC was not affected by TGF-β1. So, we consider that STAT6 activation is more 
important for enhancing CCL11 production than for modulating MAPK activation.  
We showed that TGF-β1 increased STAT6 phosphorylation in IL-4-stimulated HPDLC. 
Wenzel et al. reported that TGF-β1 did not induce STAT6 phosphorylation in human airway 
fibroblasts, although it enhanced CCL11 production in IL-13-stimulated human airway 
fibroblasts [Wenzel et al., 2002]. They also showed that TGF-β1 increased the level of 
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STAT6 phosphorylation in IL-13-stimulated human airway fibroblasts [Wenzel et al., 2002]. 
Our and Wenzel’s findings indicate that TGF-β1 enhances STAT6 activation in Th2 
cytokine-stimulated cells and might contribute to Th2-type inflammation because STAT6 
promotes Th2-associated processes [Forbes et al., 2010].  
We revealed that STAT6 is involved in CCL11 production in HPDLC. Fritz et al. reported 
that CCL11 production was abrogated in IL-4/oncostatin M-stimulated STAT6 knockout 
mouse lung fibroblasts [Fritz et al., 2006]. Hosoya et al. showed that STAT6 siRNA inhibited 
CCL11 production in IL-4/TNF-α-stimulated dermal fibroblasts [Hosoya et al., 2011]. 
Previous studies, including ours, have demonstrated that STAT6 activation is essential for 
CCL11 production in IL-4-treated cells. Myneni et al. recently reported that STAT6 is 
required for alveolar bone destruction caused by Tannerella forsythia because STAT6 
knockout mice exhibited less bone loss than wild type mice [Myneni et al., 2011]. It is 
unclear whether CCL11 is involved in alveolar bone resorption. Therefore, we should 
investigate the role of CCL11 in alveolar bone resorption in periodontal lesions in the future.  
Some previous studies have found that TGF-β1 is an immunosuppressive cytokine, which 
stimulates wound-healing processes in inflammatory lesions. For example, Chantry et al. 
reported that TGF-β1 inhibited IL-1β production in lipopolysaccharide-stimulated peripheral 
blood mononuclear cells [Chantry et al., 1989]. Musso et al. also found that TGF-β1 
downregulated IL-6 production in human monocytes that had been stimulated with IL-1β 
[Musso et al., 1990]. In the current study, we revealed that TGF-β1 enhanced CCL11 
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production in IL-4-treated HPDLC. We consider that the effects of TGF-β1 are dependent on 
the cell type and the other stimulatory factors present. Further studies are necessary to clarify 
the role of TGF-β1 in periodontal lesions.  
In summary, our results indicate the mechanism responsible for Th2 cell migration in 
periodontal lesions. Namely, TGF-β1 might contribute to the accumulation of Th2 cells in 
periodontal lesions by inducing CCL11 production. Therefore, TGF-β1 is associated with the 
pathogenesis of periodontal disease, as it induces Th2 chemokine production in resident 
periodontal cells. We also revealed that STAT6 is important for controlling CCL11 
production in HPDLC. Myneni et al. recently reported that Tannerella forsythia-induced 
alveolar bone loss was significantly reduced in STAT6 knockout mice [Garlet et al., 2010]. 
Their findings and ours indicate that the STAT6 pathway is involved in the pathogenesis of 
periodontal disease. Therefore, it might be possible to treat periodontal disease by targeting 
STAT6. However, further investigations into STAT6 are necessary because its role in 
periodontal disease, except for its effects on CCL11 production in HPDLC, are still uncertain. 
Finally, this study showed that TGF-β1 increased IL-4-induced CCL11 production in HPDLC, 
and STAT6 is essential for CCL11 release in IL-4/TGF-β1-treated HPDLC. 
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Figure legends 
Fig. 1. Effects of IL-4 and/or TGF-β1 on CCL11 production in HPDLC 
 HPDLC were stimulated with IL-4 (10 ng/ml) and/or TGF-β1 (0.01, 0.1, 1, or 10 ng/ml), 
and the resultant supernatants were collected after 24 hours’ incubation. The CCL11 levels of 
the supernatants were measured using ELISA. The results are shown as the mean and 
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standard deviation (SD) of one representative experiment performed in triplicate. The error 
bars represent SD values. * P<0.05, significantly different from the IL-4-stimulated HPDLC 
Fig. 2. Phosphorylation of p38 MAPK, ERK, and JNK in IL-4 and/or 
TGF-β1-stimulated HPDLC 
 The cultured cells were stimulated with IL-4 (10 ng/ml each) and/or TGF-β1 (10 ng/ml) for 
15, 30, or 60 minutes. The cells were lysed in lysis buffer containing protease inhibitors, and 
p38 MAPK, ERK, and JNK phosphorylation were assessed using Western blot analysis. The 
levels of phospho-p38 MAPK, total p38 MAPK, phospho-ERK, total ERK, phospho-JNK, 
and total JNK in the HPDLC were determined using Western blotting in 3 independent 
experiments. 
Fig. 3. Phosphorylation of STAT6 in IL-4 and/or TGF-β1-stimulated HPDLC  
The cultured cells were stimulated with IL-4 (10 ng/ml each) and/or TGF-β1 (10 ng/ml) for 
15, 30, or 60 minutes. The cells were lysed in lysis buffer containing protease inhibitors, and 
the phosphorylation of STAT6 was assessed using Western blot analysis. A representative 
Western blot that indicates the phospho-STAT6, total STAT6, and GAPDH levels detected in 
the HPDLC during three independent experiments is shown. 
Fig. 4. Effects of a STAT6 inhibitor on CCL11 production in IL-4 and 
TGF-β1-stimulated HPDLC 
 The cells were pre-incubated with AS1517499 (100 nM) for 1 hour and then incubated with 
IL-4 (10 ng/ml) and TGF-β1 (10 ng/ml). After 24 hours’ incubation, the supernatants were 
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collected, and CCL11 production was assessed using ELISA. The results are shown as the 
mean and SD of one representative experiment performed in triplicate. The error bars 
represent SD values. *P<0.01 significantly different from the IL-4- and TGF-β1-stimulated 
HPDLC that were not treated with the inhibitor 
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